Substance / Medication

Cephalexin

Overview

Active Ingredient
cephalexin
RxNorm CUI
2231

Indications

Cephalexin capsules are indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Streptococcus pneumoniae Respiratory tract infections caused byand (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the eff

Labeler: American Antibiotics, IncUpdated: 2011-06-20T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Cephalexin capsules are contraindicated in patients with known allergy to the cephalosporin group of antibiotics.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

14 trials linked to this intervention

14
Total Trials
1
Recruiting
1
With Results

Research Evidence

Published studies and systematic reviews

Sort:
High-dose cephalexin for cellulitis: a pilot randomized controlled trial.
Yadav Krishan, Eagles Debra, Perry Jeffrey J et al. · CJEM · 2023
PMID: 36592299RCTFull text (PMC)
Effect of oral cephalexin in the treatment of BCG lymphadenitis.
Ayazi Parviz, Mahyar Abolfazl, Taremiha Alireza et al. · Infez Med · 2014
PMID: 24955797RCT
Three-ways crossover bioequivalence study of cephalexin in healthy Malay volunteers.
Liew Kai Bin, Peh Kok Khiang, Loh Gabriel Onn Kit et al. · Drug Dev Ind Pharm · 2014
PMID: 23688276RCT
Effects of amlodipine on the oral bioavailability of cephalexin and cefuroxime axetil in healthy volunteers.
Ding Yi, Liu WenXing, Jia YanYan et al. · J Clin Pharmacol · 2013
PMID: 23400747RCT
The effect of staggered administration of zinc sulfate on the pharmacokinetics of oral cephalexin.
Ding Yi, Jia Yan-Yan, Li Fan et al. · Br J Clin Pharmacol · 2012
PMID: 22023069RCTFull text (PMC)
Effects of sodium bicarbonate and ammonium chloride pre-treatments on PEPT2 (SLC15A2) mediated renal clearance of cephalexin in healthy subjects.
Liu Rui, Tang Audrey May Yi, Tan Yen Ling et al. · Drug Metab Pharmacokinet · 2011
PMID: 21084767RCT
Bioavailability and pharmacokinetics of a novel cephalexin oral paste formulation in fed and fasted dogs.
Chicoine A, Cox W, Huang L et al. · J Vet Pharmacol Ther · 2009
PMID: 19614847RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Cefalexin (substance)
SNOMED CT
387304003
UMLS CUI
C0007716
RxNorm CUI
2231
Labeler
American Antibiotics, Inc

Clinical Data

This intervention maps to 15 entities in the Healos knowledge graph.

15
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
14
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.